SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
stocks
Big four bank holds up in weakening economic conditions
stocks
Our view after Coles’ shares plunge
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,008.90 | 31.70 | 0.35% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,863.48 | 120.50 | -0.23% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,468.33 | 303.97 | 1.21% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,720.26 | 21.63 | 0.16% |
| S&P 500 | 7,590.97 | 49.57 | 0.66% |
| S&P/ASX 200 | 8,886.80 | 30.30 | 0.34% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |